MEDICALLY REVIEWED

Breakthrough Therapy: What You Need to Know about HIBRUKA (Orelabrutinib)

Orelabrutinib
InnoCare Pharma announced the approval of HIBRUKA (Orelabrutinib) by the HSA of Singapore for the treatment of adult patients with r/r MCL

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

PMDD
Premenstrual Dysphoric Disorder (PMDD): The Severe Form of PMS

Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome (PMS) that affects approximately 3-8% of women of reproductive age. The condition is characterised by emotional and physical symptoms that occur during the luteal phase of the menstrual cycle, and can significantly impact a woman’s quality of life.

Read More »
Malaysia mental health
Young Malaysians Show Moderate Mental Health, Study Reveals

A recent study by the Institute for Youth Research Malaysia (IYRES) has highlighted that the overall mental health of Malaysian youths is moderately satisfactory. According to the Malaysian Youth Mental Health Index 2023 (MyMHI23), young individuals aged between 15 and 30 scored an average of 71.91. This figure provides early indications of potential mental health challenges within this demographic.

Read More »